Showing results (741-750 of 887) with videos related to
Sort By:
Pageof 89
Plos One|October 23, 2008
Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytesFeng Cao, Roger A Wagner, Kitchener D Wilson, et al.The New England Journal of Medicine|August 13, 2004
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CMLCatriona H M Jamieson, Laurie E Ailles, Scott J Dylla, et al.Proceedings of the National Academy of Sciences of the United States of America|January 15, 2011
VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migrationOlga V Razorenova, Elizabeth C Finger, Renata Colavitti, et al.Melanoma Research|June 18, 2019
Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockadeKatie L Anderson, Kristin M Snyder, Daisuke Ito, et al.Blood|April 25, 2012
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigenSebastian Ochsenreither, Ravindra Majeti, Thomas Schmitt, et al.Science (New York, N.Y.)|April 18, 2015
Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potentialYuval Rinkevich, Graham G Walmsley, Michael S Hu, et al.Nature Protocols|May 12, 2018
Isolation and functional assessment of mouse skeletal stem cell lineageGunsagar S Gulati, Matthew P Murphy, Owen Marecic, et al.Nature Cancer|November 21, 2022
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effectYoko Nishiga, Alexandros P Drainas, Maya Baron, et al.Proceedings of the National Academy of Sciences of the United States of America|July 14, 2021
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab toleranceRosalynd Upton, Allison Banuelos, Dongdong Feng, et al.Science (New York, N.Y.)|June 1, 2013
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodiesKipp Weiskopf, Aaron M Ring, Chia Chi M Ho, et al.Pageof 89